CSIMarket
 
Biomerica Inc   (NASDAQ: BMRA)
Other Ticker:  
 
 
Price: $3.2000 $-0.12 -3.614%
Day's High: $3.48 Week Perf: -6.43 %
Day's Low: $ 3.13 30 Day Perf: -8.43 %
Volume (M): 59 52 Wk High: $ 10.16
Volume (M$): $ 190 52 Wk Avg: $3.51
Open: $3.21 52 Wk Low: $1.93



 Market Capitalization (Millions $) 7
 Shares Outstanding (Millions) 2
 Employees 64
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0

Biomerica Inc
Biomerica Inc is a California-based medical diagnostic company that develops, manufactures, and distributes diagnostic tests for various diseases and conditions. The company's products cover a wide range of fields, including gastrointestinal, food intolerance, and diabetes. Biomerica's tests are designed to be easy to use, accurate, and cost-effective, making them suitable for use in both clinical settings and at home. The company's goal is to improve healthcare globally by providing accessible and reliable diagnostic solutions.


   Company Address: 17571 Von Karman Avenue Irvine 92614 CA
   Company Phone Number: 645-2111   Stock Exchange / Ticker: NASDAQ BMRA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
MYGN   -3.08%    
QDEL   -4.34%    
ABT        1.66% 
CDNA   -5.73%    
DGX        2.45% 
FLGT   -5.14%    
• View Complete Report
   



Stock Market Announcement

Nasdaq Grants Biomerica 180-Day Extension for Listing Compliance Amid Product Development Efforts,

Published Thu, Nov 7 2024 2:09 PM UTC

Biomerica Granted 180-Day Extension by Nasdaq to Regain Listing Compliance Amidst Product ExpansionBiomerica, Inc. (Nasdaq: BMRA), a prominent player in the medical diagnostics industry, has been given a lifeline by the Nasdaq Stock Market LLC with a 180-day extension to comply with its listing requirements. The announcement came on November 7, 2024, providing the company un...

Product Service News

Pioneering a Path to Comfort Biomericas Game-Changing IBS Solution Now Available at Home

Published Mon, Jul 1 2024 11:47 AM UTC

Biomerica Inc., a leading global provider of advanced medical products, has recently unveiled a groundbreaking innovation that promises to significantly improve the lives of millions suffering from Irritable Bowel Syndrome (IBS). The company has launched an at-home sample collection feature for its highly acclaimed inFoods IBS system, aiming to simplify and revolutionize the...

Biomerica Inc

Biomerica Inc reports a loss of $-0.11 per share in the third quarter of fiscal 20242.

Biomerica Inc, a global provider of medical diagnostic and therapeutic products, recently reported their financial results for the third quarter of fiscal 2024. Unfortunately, the company experienced a decrease in revenue and an increased loss compared to the previous year. The lower orders led to a vanishing revenue of $1.02 million, a decrease of -8.497% year-on-year. Additionally, the company reported a net loss of $-0.11 per share, larger than the loss of $-0.09 per share in the previous financial period.
In contrast to Biomerica Inc's financial performance, the overall In Vitro & In Vivo Diagnostic Substances sector saw a revenue increase of 10.62% in the third quarter of 2024 compared to the same period the previous year. This indicates that Biomerica Inc faced challenges specific to their business or industry.

Product Service News

Biomerica Pioneers Groundbreaking Solutions in Medical Diagnostics

Published Mon, May 13 2024 12:19 PM UTC

Biomerica, Inc. continues to push the boundaries of medical diagnostics with recent announcements that demonstrate their commitment to revolutionizing healthcare. The company, which specializes in advanced diagnostic and therapeutic products, has unveiled two significant milestones that have the potential to transform the landscape of medical testing.Firstly, Biomerica recen...

Partnership

Biomerica Inc. and UAE Healthcare Conglomerate Join Forces to Revolutionize Colorectal and Breast Screening

Published Mon, Apr 29 2024 12:19 PM UTC

Biomerica Inc. has recently entered into an exclusive multi-year distribution agreement with a prominent healthcare conglomerate in the United Arab Emirates (UAE). The partnership aims to significantly enhance the accessibility and efficiency of colorectal cancer screening and breast examination technologies in the region. This strategic alliance has the potential to revolut...







Biomerica Inc's Segments
Clinical Lab    47.49 % of total Revenue
Over-the-counter    36.43 % of total Revenue
Contract Manufacturing    15.89 % of total Revenue
Physician s Office    0.18 % of total Revenue
Asia    26.34 % of total Revenue
North America    33.68 % of total Revenue
Europe    19.01 % of total Revenue
Middle East    20.84 % of total Revenue
South America    0.12 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com